Ganli Pharmaceutical
Gan &a; Lee pharmaceutical is a Chinese high-tech biopharmaceutical company engaged in the R&a;D of insulin glargine and insulin lispro.
Business Model:
Revenue: $0
Employees: 1,001-5,000
Rankings
Industries / Tags:
Detailed Ganli Pharmaceutical Information
Geographic Data
Address: No. 8 Jingsheng North 3rd Street
City: Beijing
State: beijing municipality
Zip: 101102
Country: CN
Financial Info
Stage:
private equity
Raised Last:
$0
Raised Total:$46M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Founded in 1998, Gan &a; Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China. Since its inauguration, Gan &a; Lee has been focusing on insulin production. In 1998, Gan &a; Lee successfully developed the first domestic biosynthetic human insulin, which was evaluated as China’s top 10 scientific and technological breakthroughs by Chinese Academy of Sciences and Engineering. Hitherto Gan &a; Lee has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin®, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25®, all of which have received high reputation from nationwide clinicians and patients, with outstanding efficacy and safety guarantees.
Contact Phone:
Contact Email:
Ganli Pharmaceutical went public on 6/28/2020 on the Shanghai Stock Exchange
Listed Exchange:
Shanghai Stock Exchange
IPO Date:
6/28/2020
Ticker Symbol:
603087
IPO Price:
$63.32/share
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2021 | Sepax Technologies | Series D | 0 |
| 11/2021 | Sepax Technologies | Series D | 0 |
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2015 | Private Equity Round | 1 | - |
Hillhouse Capital Group Hillhouse Capital Group |
2/2012 | Series B | 1 | - |
Qiming Venture Partners Qiming Venture Partners |
6/2020 | IPO | $360M |
|
5/2011 | Series B | 3 | $30.2M |
Goldman Sachs Qiming Venture Partners Tengye Ventures Goldman Sachs Qiming Venture Partners Tengye Ventures |
12/2009 | Series A | 1 | $16.2M |
Qiming Venture Partners Qiming Venture Partners |
1/2015 | Private Equity Round | 1 | - |
Hillhouse Capital Group Hillhouse Capital Group |
2/2012 | Series B | 1 | - |
Qiming Venture Partners Qiming Venture Partners |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
